TearSolutions, Inc

TearSolutions, LLC is developing a novel ocular tear generation therapy for 'dry eye' disease through phase II human clinical trials. The platform technology is centered on the tear protein 'lacritin' and the proprietary drug 'Lacripep'. An outsourcing model is being used. Lacritin was discovered by the co-founder at the University of Virginia. TearSolutions is lead by co-founder/CEO/president Mark Logan.